KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis.

Eric L Simpson, Jonathan I Silverberg, Robert Bissonnette, Linda Stein Gold, April Armstrong, Adelaide A Hebert, Rocco T Serrao, Jeannette R Jakus, Philip M Brown, David S Rubenstein, Stephen C Piscitelli, Anna M Tallman, Lawrence F Eichenfield

J Drugs Dermatol 24(6) 600-607

PMID40465504
PMCID-
DOI10.36849/JDD.8860
发表日期2025-06-04
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: In the ADORING 1 and 2 phase 3 trials, tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in adults and children down to 2 years of age with atopic dermatitis (AD). Here we evaluate the time to onset of itch relief in the trials. METHODS: Eight hundred thirteen (813) patients were randomized to tapinarof cream 1% or vehicle QD for 8 weeks. Pruritus relief was assessed by Peak Pruritus Numerical Rating Scale (PP-NRS) scores (daily and by visit at weeks 1, 2, 4, and 8). RESULTS: Mean baseline PP-NRS scores in ADORING 1 and 2 were 6.7 and 6.8, respectively. Greater reductions in mean daily PP-NRS scores were observed for tapinarof vs vehicle as early as day 1, 24 hours after initial application (-1.2 vs -1.0; pooled post hoc analysis), with significant improvements at day 2 (-1.6 vs -1.1, P=0.0115). Daily pruritus improvements continued through week 8. Significantly greater reductions in mean weekly PP-NRS scores with tapinarof vs vehicle were demonstrated at week 1 in ADORING 1, -2.0 vs -1.2 (P<0.0001) and ADORING 2, -2.0 vs -1.3 (P=0.0010), continuing through week 8, -4.1 vs -2.6 and -4.1 vs -2.4 (both P<0.0001). CONCLUSION: Tapinarof demonstrated rapid and clinically meaningful pruritus relief in patients with AD, with improvements starting 24 hours after initial application and statistically significant improvements at day 2. CITATION: Simpson EL, Silverberg JI, Bissonnette R, et al. Rapid onset of itch relief with tapinarof in two phase 3 trials in atopic dermatitis. J Drugs Dermatol. 2025;24(6):600-607. doi:10.36849/JDD.8860R1.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。